BioNeutral Group Inc. to Present at the Rodman & Renshaw 12th Annual Global Investment Conference

Published on Wednesday, 08 September 2010 09:28 Written by TradersHuddle Staff

NEWARK, N.J., Sept. 8, 2010 (GLOBE NEWSWIRE) -- BioNeutral Group Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, today announced that Dr. Andy Kielbania, Chief Scientist at BioNeutral is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference at 9:35 a.m. ET on September 15, 2010 in the Wilslow Salon at the New York Palace Hotel in New York. Dr. Kielbania will be available during the day on September 13 for one-on-one meetings. Please contact your Rodman & Renshaw representative to schedule a meeting.

Dr. Kielbania will provide an overview of the Company's product pipeline, development status, and upcoming milestones. BioNeutral has developed a technology platform and two product families, with a portfolio of applications to address a wide range of issues associated with the elimination of a wide variety of noxious and toxic gases, the removal of permanent stains, and the eradication of a broad spectrum of harmful microorganisms focused upon protecting the environment and saving lives. Based upon its versatile and easy to customize technology platform, BioNeutral has developed over 30 superior products.

Investors and other interested parties may access the live presentation at http://www.wsw.com/webcast/rrshq18/bonu.

About Rodman & Renshaw

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. We also provide research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene and Ogiene, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. Ogiene™ based AutoNeutral™ Odor Eliminator is currently commercially available in the United States. For more information, see www.bioneutralgroup.com

Forward-Looking Statements

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward looking statements are often identified by the use of forward-looking terminology such as "believes," expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

CONTACT:  Stern & Co.
          PR/Media Relations:
          Richard Stern
          212-888-0044 
          
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
 
 
          Hayden IR
          Investor Relations:
          Brett Maas
          646/536-7331
          
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
 

          BioNeutral Group Inc.
          Stephen J. Browand, President and CEO
          973-286-2899
          
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.